Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMBR | P28336 | 5/20 | 0.74 |
| ▸ | TACR1 | P25103 | 1/20 | 0.74 |
| ▸ | MAPT | P10636 | 1/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.71 |
| ▸ | ACE | P12821 | 4/20 | 0.67 |
| ▸ | ECE1 | P42892 | 6/20 | 0.65 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.65 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.61 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.61 |
| ▸ | ITGAL | P20701 | 1/20 | 0.61 |
| ▸ | MME | P08473 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19359093 | 1.00 | NMBR (0.74) | NMBRTACR1MAPTSMN1; SMN2ACE | |
| SCHEMBL2228491 | 1.00 | NMBR (0.74) | NMBRTACR1MAPTSMN1; SMN2ACE | |
| SCHEMBL18558611 | 0.89 | MAPT (0.72) | NMBRTACR1MAPTSMN1; SMN2 | |
| SCHEMBL11370921 | 0.88 | ALOX15 (0.67) | TACR1MAPTSMN1; SMN2ACEECE1 | |
| SCHEMBL11370918 | 0.88 | ALOX15 (0.67) | TACR1MAPTSMN1; SMN2ACEECE1 | |
| SCHEMBL6899047 | 0.88 | NMBR (0.73) | NMBRTACR1MAPTSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL27463103 | 0.87 | ALOX15 (0.66) | TACR1MAPTSMN1; SMN2ACEECE1 | |
| SCHEMBL753982 | 0.87 | ALOX15 (0.72) | TACR1ACEECE1ALOX15ITGB2 | |
| SCHEMBL11369419 | 0.87 | ALOX15 (0.72) | TACR1ACEECE1ALOX15ITGB2 | |
| SCHEMBL27403392 | 0.87 | ALOX15 (0.72) | TACR1ACEECE1ALOX15ITGB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3429354-A1 | B-VITAMIN AND AMINO ACID CONJUGATES OF NICOTINOYL RIBOSIDES AND REDUCED NICOTINOYL RIBOSIDES, DERIVATIVES THEREOF, AND METHODS OF PREPARATION THEREOF | Chromadex Inc. (US) | 2019-01-23 | — | — | EP | claimed |
| WO-2017161165-A1 | B-VITAMIN AND AMINO ACID CONJUGATES OF NICOTINOYL RIBOSIDES AND REDUCED NICOTINOYL RIBOSIDES, DERIVATIVES THEREOF, AND METHODS OF PREPARATION THEREOF | ChromaDex Inc. (US) | 2017-09-21 | — | — | WO | claimed |
| EP-3265448-A1 | RILUZOLE PRODRUGS AND THEIR USE | Biohaven Pharmaceutical Holding Company Ltd. (US) | 2018-01-10 | — | — | EP | disclosed |
| WO-2016140879-A9 | RILUZOLE PRODRUGS AND THEIR USE | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. (US) | 2016-11-03 | — | — | WO | disclosed |
| EP-1377542-B1 | HIV PROTEASE INHIBITORS BASED ON AMINO ACID DERIVATIVES | AMBRILIA BIOPHARMA INC (CA) | 2007-08-01 | — | — | EP | disclosed |
| EP-1803706-A1 | HIV protease inhibitors based on amino acid derivatives | Ambrilia Biopharma Inc. (CA) | 2007-07-04 | — | — | EP | disclosed |
| US-6677367-B2 | LYSINE DERIVATIVE WITH 2-AMINOSULFONYLTHIOPHENE SUBSTITUENT; ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS) VIRICIDES | PHARMACOR INC. (CA) | 2004-01-13 | — | — | US | disclosed |
| EP-1377542-A1 | HIV PROTEASE INHIBITORS BASED ON AMINO ACID DERIVATIVES | Pharmacor Inc. (CA) | 2004-01-07 | — | — | EP | disclosed |
| US-6656965-B2 | In particular N-epsilon-amino acid substituted L-lysine derivatives possessing aspartyl protease inhibitory properties. | PHARMACOR INC. (CA) | 2003-12-02 | — | — | US | disclosed |
| US-20030195159-A1 | HIV protease inhibitors based on amino acid derivatives | TAIMED BIOLOGICS, INC. (TW) | 2003-10-16 | — | — | US | disclosed |
| US-6610689-B2 | Viricides | PHARMACOR INC. (CA) | 2003-08-26 | — | — | US | disclosed |
| US-6608100-B1 | N-epsilon-amino acid substituted L-lysine sulfonamide derivatives possessing aspartyl protease inhibitory properties | PHARMACOR INC. (CA) | 2003-08-19 | — | — | US | disclosed |
| US-20030144265-A1 | HIV protease inhibitors based on amino acid derivatives | TAIMED BIOLOGICS, INC. (TW) | 2003-07-31 | — | — | US | disclosed |
| US-20030119803-A1 | HIV protease inhibitors based on amino acid derivatives | TAIMED BIOLOGICS, INC. (TW) | 2003-06-26 | — | — | US | disclosed |
| US-6506786-B2 | Such as N-isobutyl-N-(4-methylbenzene-sulfonyl)-N-(N-(4-methylbenzenesulfonyl)-L -phenylalanyl)-L-lysine | PHARMACOR INC. (CA) | 2003-01-14 | — | — | US | disclosed |
| WO-2002064551-A1 | HIV PROTEASE INHIBITORS BASED ON AMINO ACID DERIVATIVES | PHARMACOR INC. (CA) | 2002-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144265-A1 | HIV protease inhibitors based on amino acid derivatives | ANPEP, PEPD, XPNPEP1 | NMBR 4725/4885TACR1 2181/4885MAPT 2981/4885 |
| US-20030195159-A1 | HIV protease inhibitors based on amino acid derivatives | ANPEP, PEPD, XPNPEP1 | NMBR 4725/4885TACR1 2181/4885MAPT 2981/4885 |
| US-20030119803-A1 | HIV protease inhibitors based on amino acid derivatives | ANPEP, PEPD, XPNPEP1 | NMBR 4725/4885TACR1 2181/4885MAPT 2981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.